Clinical Trial Update: Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing momelotinib to ruxolitinib in myelofibrosis subjects has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Momelotinib (momelotinib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Status: COMPLETED | Results posted: 2023-05-12